Li Yan-Qi, Zheng Zhi, Liu Quan-Xing, Lu Xiao, Zhou Dong, Zhang Jiao, Zheng Hong, Dai Ji-Gang
Department of Thoracic Surgery, Xinqiao Hospital, Army Medical University (Third Military Medical University), Chongqing, 400037, China.
World J Surg Oncol. 2021 Apr 10;19(1):109. doi: 10.1186/s12957-021-02229-y.
Ezrin-radixin-moesin (ERM) have been explored in many cancer processes. Moesin, as its component, has also been found to play an important role in the prognosis of cancer patients, tumor metastasis, drug resistance, and others. Especially in regulating the immunity, but most results came from direct studies on immune cells, there is no clear conclusion on whether moesin has similar effects in tumor cells. And moesin has certain research results in many cancers in other aspects, but there are few about moesin in lung adenocarcinoma (LUAD).
We detect the expression of moesin in 82 LUAD and matched normal tissue samples by immunohistochemistry. Besides, for the pathological feature, we did a detailed statistical analysis. And with the help of various databases, we have done in-depth exploration of moesin's ability to enhance the extent of immune lymphocyte infiltration.
Moesin is a poor expression in lung cancer tissues than the corresponding normal samples. And this phenomenon had a strongly associated with the prognosis and TNM stage of these LUAD patients. Moesin can enhance the infiltration of multiple immune lymphocytes in lung cancer. And this may be related to the interaction between moesin and various inflammatory molecules.
Moesin is a newly index for the prognosis of LUAD and improves the prognosis of LUAD patients by regulating a variety of inflammation-related molecules to enhance immune lymphocytes infiltration.
埃兹蛋白-根蛋白-膜突蛋白（ERM）已在多种癌症进程中得到研究。膜突蛋白作为其组成部分，也被发现在癌症患者的预后、肿瘤转移、耐药性等方面发挥重要作用。特别是在调节免疫方面，但大多数结果来自对免疫细胞的直接研究，关于膜突蛋白在肿瘤细胞中是否有类似作用尚无明确结论。而且膜突蛋白在许多癌症的其他方面有一定研究成果，但关于肺腺癌（LUAD）中膜突蛋白的研究较少。
我们通过免疫组织化学检测了82例LUAD及配对的正常组织样本中膜突蛋白的表达。此外，对于病理特征，我们进行了详细的统计分析。并借助各种数据库，对膜突蛋白增强免疫淋巴细胞浸润程度的能力进行了深入探索。
膜突蛋白在肺癌组织中的表达低于相应的正常样本。并且这种现象与这些LUAD患者的预后和TNM分期密切相关。膜突蛋白可增强肺癌中多种免疫淋巴细胞的浸润。这可能与膜突蛋白与各种炎症分子之间的相互作用有关。
膜突蛋白是LUAD预后的一个新指标，通过调节多种炎症相关分子来增强免疫淋巴细胞浸润，从而改善LUAD患者的预后。
